Top

Published in:

Open Access 01-12-2021 | Care | Research article

Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care

Authors: Sarah F. Christensen, Robyn M. Scherber, Gina L. Mazza, Amylou C. Dueck, Nana Brochmann, Christen L. Andersen, Hans C. Hasselbalch, Ruben A. Mesa, Holly L. Geyer

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Patients with Philadelphia-negative Myeloproliferative Neoplasms (MPN) suffer from numerous symptoms and decreased quality of life. Smoking is associated with an increased symptom burden in several malignancies. The aim of this study was to analyze the association between smoking and MPN-related symptom burden and explore MPN patients’ opinions on smoking.

Methods

A total of 435 patients with MPN participated in a cross-sectional internet-based survey developed by the Mayo Clinic and the Myeloproliferative Neoplasm Quality of Life Group. Patients reported their demographics, disease characteristics, tobacco use, and opinions on tobacco use. In addition, MPN-related symptoms were reported via the validated 10-item version of the Myeloproliferative Neoplasms Symptom Assessment Form.

Results

Current/former smokers reported worse fatigue (mean severity 5.6 vs. 5.0, p = 0.02) and inactivity (mean severity 4.0 vs. 3.4, p = 0.03) than never smokers. Moreover, current/former smokers more frequently experienced early satiety (68.5% vs. 58.3%, p = 0.03), inactivity (79.9% vs. 71.1%, p = 0.04), and concentration difficulties (82.1% vs. 73.1%, p = 0.04). Although not significant, a higher total symptom burden was observed for current/former smokers (mean 30.4 vs. 27.0, p = 0.07). Accordingly, overall quality of life was significantly better among never smokers than current/former smokers (mean 3.5 vs. 3.9, p = 0.03). Only 43.2% of the current/former smokers reported having discussed tobacco use with their physician, and 17.5% did not believe smoking increased the risk of thrombosis.

Conclusion

The current study suggests that smoking may be associated with increased prevalence and severity of MPN symptoms and underscores the need to enhance patient education and address tobacco use in the care of MPN patients.

Available only for authorised users

Mokdad A, Marks J, Stroup D, Gerberding J. Actual causes of death in the United States, 2000. J Am Med Assoc. 2004;291(10):1238–46. https://doi.org/10.1001/jama.291.10.1238.CrossRef

West R. Tobacco smoking: health impact, prevalence, correlates and interventions. Psychol Health. 2017;32(8):1018–36. https://doi.org/10.1080/08870446.2017.1325890.CrossRefPubMedPubMedCentral

U.S. Department of Health and Human Services, The Health Consequences of Smoking- 50 Years of Progress: A Report of the Surgeon General, 2014. http://www.cdc.gov/tobacco/data_statistics/sgr/50th-anniversary/index.htm. Accessed 2 May 2019.

Csordas A, Bernhard D. The biology behind the atherothrombotic effects of cigarette smoke. Nat Rev Cardiol. 2013;10(4):219–30. https://doi.org/10.1038/nrcardio.2013.8.CrossRefPubMed

Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010;34(3):J258–65. https://doi.org/10.1016/j.jaut.2009.12.003.CrossRefPubMed

Rom O, Avezov K, Aizenbud D, Reznick AZ. Cigarette smoking and inflammation revisited. Respir Physiol Neurobiol. 2013;187(1):5–10. https://doi.org/10.1016/j.resp.2013.01.013.CrossRefPubMed

Pedersen KM, Bak M, Sørensen AL, Zwisler AD, Ellervik C, Larsen MK, et al. Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study. Cancer Med. 2018;7(11):1–7. https://doi.org/10.1002/cam4.1815.CrossRef

Yanbaeva D, Dentener M, Creutzberg E, Wesseling G, Wouters E. Systemic effects of smoking. Chest. 2007;131(5):1557–66. https://doi.org/10.1378/CHEST.06-2179.CrossRefPubMed

Hasselbalch HC, Bjørn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediat Inflamm. 2015;2015:1–16. https://doi.org/10.1155/2015/102476.CrossRef

10.

Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356–63. https://doi.org/10.1200/JCO.2010.32.9490.CrossRefPubMed

11.

Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, et al. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol. 2017;10(1):1–8. https://doi.org/10.1186/s13045-017-0425-z.CrossRef

12.

Lindholm Sørensen A, Hasselbalch HC. Smoking and Philadelphia-negative chronic myeloproliferative neoplasms. Eur J Haematol. 2016;97(1):63–9. https://doi.org/10.1111/ejh.12684.CrossRefPubMed

13.

Hasselbalch HC. Smoking as a contributing factor for development of polycythemia vera and related neoplasms. Leuk Res. 2015;39(11):1137–45. https://doi.org/10.1016/j.leukres.2015.09.002.CrossRef

14.

Duncombe AS, Anderson LA, James G, de Vocht F, Fritschi L, Mesa R, et al. Modifiable lifestyle and Medical risk factors associated with Myeloproliferative neoplasms. HemaSphere. 2020;4(1):e327. https://doi.org/10.1097/hs9.0000000000000327.CrossRefPubMedPubMedCentral

15.

Jayasuriya NA, Kjaergaard AD, Pedersen KM, Sørensen AL, Bak M, Larsen MK, et al. Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2·3 million people. Br J Haematol. 2020;189(2):323–34. https://doi.org/10.1111/bjh.16321.CrossRefPubMed

16.

Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017;130(1):2475–83. https://doi.org/10.1182/asheducation-2017.1.470.CrossRefPubMed

17.

Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68–76. https://doi.org/10.1002/cncr.22365.CrossRefPubMed

18.

Geyer HL, Dueck AC, Scherber RM, Mesa RA. Impact of inflammation on Myeloproliferative neoplasm symptom development. Mediat Inflamm. 2015;2015:1–9. https://doi.org/10.1155/2015/284706.CrossRef

19.

Geyer H, Mesa RA. Approach to MPN symptom assessment. Curr Hematol Malig Rep. 2017;12(5):381–8. https://doi.org/10.1007/s11899-017-0399-5.CrossRefPubMedPubMedCentral

20.

Dieperink KB, Hansen S, Wagner L, Johansen C, Andersen KK, Hansen O. Living alone, obesity and smoking: important factors for quality of life after radiotherapy and androgen deprivation therapy for prostate cancer. Acta Oncol (Madr). 2012;51(6):722–9. https://doi.org/10.3109/0284186X.2012.682627.CrossRef

21.

Peppone LJ, Mustian KM, Morrow GR, Dozier AM, Ossip DJ, Janelsins MC, et al. The effect of cigarette smoking on Cancer treatment-related side effects. Oncologist. 2011;16(12):1784–92. https://doi.org/10.1634/theoncologist.2011-0169.CrossRefPubMedPubMedCentral

22.

Dhalla S, Kopec JA. The CAGE questionnaire for alcohol misuse: a review of reliability and validity studies. Clin Investig Med. 2007;30(1):33–41. https://doi.org/10.25011/cim.v30i1.447.CrossRef

23.

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J. Clin. Oncol. 2012. https://doi.org/10.1200/JCO.2012.42.3863.

24.

Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey. Ann Hematol. 2017;96(10):1653–65. https://doi.org/10.1007/s00277-017-3082-y.CrossRefPubMedPubMedCentral

25.

Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;96(1):145–62. https://doi.org/10.1002/ajh.26050.CrossRefPubMed

26.

Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599–613. https://doi.org/10.1002/ajh.26008.CrossRefPubMed

27.

Christensen SF, Scherber RM, Brochmann N, Goros M, Gelfond J, Andersen CL, et al. Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association. Cancers (Basel). 12(2020):2202. https://doi.org/10.3390/cancers12082202.

28.

Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, et al. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer. 2016;122(3):477–85. https://doi.org/10.1002/cncr.29753.CrossRefPubMed

29.

Brochmann N, Flachs EM, Christensen AI, Bak M, Andersen CL, Juel K, et al. Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. Clin Epidemiol. 2019;11:23–33. https://doi.org/10.2147/CLEP.S162688.CrossRefPubMed

30.

Karam-Hage M, Cinciripini PM, Gritz ER. Tobacco use and cessation for cancer survivors: an overview for clinicians. CA Cancer J Clin. 2014;64(4):272–90. https://doi.org/10.3322/caac.21231.CrossRefPubMedPubMedCentral

31.

Garces YI, Yang P, Parkinson J, Zhao X, Wampfler JA, Ebbert JO, et al. The relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest. 2004;126(6):1733–41. https://doi.org/10.1378/chest.126.6.1733.CrossRefPubMed

32.

Vaidya R, Gangat N, Jimma T, Finke CM, Lasho TL. Plasma cytokines in polycythemia vera : Phenotypic correlates , prognostic relevance , and comparison with myelofibrosis. 2012:1003–5. https://doi.org/10.1002/ajh.23295.

33.

Pourcelot E, Trocme C, Mondet J, Bailly S, Toussaint B, Mossuz P. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42(5):360–8. https://doi.org/10.1016/j.exphem.2014.01.006.CrossRefPubMed

34.

Iho S, Tanaka Y, Takauji R, Kobayashi C, Muramatsu I, Iwasaki H, et al. Nicotine induces human neutrophils to produce IL-8 through the generation of peroxynitrite and subsequent activation of NF-?B. J. Leukoc. Biol. 74(2003):942–51. https://doi.org/10.1189/jlb.1202626.

35.

Bower JE, Ganz PA, Irwin MR, Kwan L, Breen EC, Cole SW. Inflammation and Behavioral Symptoms After Breast Cancer Treatment : Do Fatigue, Depression , and Sleep Disturbance Share a Common Underlying Mechanism? J Clin Oncol. 2011;29(26):3517–22. https://doi.org/10.1200/JCO.2011.36.1154.CrossRefPubMedPubMedCentral

36.

Leifert JA. Anaemia and cigarette smoking. Int J Lab Hematol. 2008;30(3):177–84. https://doi.org/10.1111/j.1751-553X.2008.01067.x.CrossRefPubMed

37.

Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92(S6):1684–8. https://doi.org/10.1002/1097-0142(20010915)92:6+<1684::AID-CNCR1497>3.0.CO;2-Z.

38.

Panagiotakos DB, Pitsavos C, Chrysohoou C, Kavouras S, Stefanadis C. The associations between leisure-time physical activity and inflammatory and coagulation markers related to cardiovascular disease: the ATTICA study. Prev Med (Baltim). 2005;40(4):432–7. https://doi.org/10.1016/j.ypmed.2004.07.010.CrossRef

39.

Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96(2):315–8. https://doi.org/10.3324/haematol.2010.031070.CrossRefPubMed

40.

Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104(4):788–93. https://doi.org/10.1002/cncr.21234.CrossRefPubMed

41.

Daniel M, Keefe FJ, Lyna P, Peterson B, Garst J, Kelley M, et al. Persistent smoking after a diagnosis of lung Cancer is associated with higher reported pain levels. J Pain. 2010;10:323–8. https://doi.org/10.1016/j.jpain.2008.10.006.Persistent.CrossRef

42.

Heikkinen H, Jallinoja P, Saarni S, Patja K. The impact of smoking on health-related and overall quality of life: a general population survey in Finland. Nicotine Tob Res. 2008;10(7):1199–207. https://doi.org/10.1080/14622200802163142.CrossRefPubMed

43.

Lang I, Gardener E, Huppert FA, Melzer D. Was John Reid right? Smoking, class, and pleasure: a population-based cohort study in England. Public Health. 2007;121(7):518–24. https://doi.org/10.1016/j.puhe.2007.01.005.CrossRefPubMed

44.

Picciotto MR, Brunzell DH, Caldarone BJ. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport. 2002;13(9):1097–106. https://doi.org/10.1097/00001756-200207020-00006.CrossRefPubMed

45.

Foster JH, Powell JE, Marshall EJ, Peters TJ. Quality of life in alcohol-dependent subjects - a review. Qual Life Res. 1999;8(3):255–61. https://doi.org/10.1023/A:1008802711478.CrossRefPubMed

46.

Roerecke M, Rehm J. Alcohol consumption, drinking patterns, and ischemic heart disease: a narrative review of meta-analyses and a systematic review and meta-analysis of the impact of heavy drinking occasions on risk for moderate drinkers. BMC Med. 2014;12(1):1–11. https://doi.org/10.1186/s12916-014-0182-6.CrossRef

47.

Ramaswamy AT, Toll BA, Chagpar AB, Judson BL. Smoking, cessation, and cessation counseling in patients with cancer: a population-based analysis. Cancer. 2016;122(8):1247–53. https://doi.org/10.1002/cncr.29851.CrossRefPubMed

48.

Brochmann N, Flachs EM, Christensen AI, Andersen CL, Juel K, Hasselbalch HC, et al. A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents. Clin. Epidemiol. 2017;9:141–50. https://doi.org/10.2147/CLEP.S117587.CrossRefPubMedPubMedCentral

49.

Shields PG, Bierut L, Herbst RS, Arenberg D, Benowitz NL, Cinciripini PM, Collins B, Collins B, David S, Davis J, Hitsman B, Jaklitsch MT, Lang M, Levinson AH, McCarthy DE, Park ER, Selzle J, Sheffer CE, Spencer S, Tanvetyanon T, Tiep B, Tindle HA, Urbanic J, Warner D, Hooper MW, Whitlock CW, Wood DE, National Comprehensive Cancer Network®. Smoking Cessation: NCCN Clinical Practice Guidelines in Oncology. 2019;2:1–69.

50.

Kaur G, Pinkston R, McLemore B, Dorsey WC, Batra S. Immunological and toxicological risk assessment of e-cigarettes. Eur. Respir. Rev. 27(2018). https://doi.org/10.1183/16000617.0119-2017.

51.

Ramanathan G, Craver-hoover B, Arechavala RJ, Herman DA, Chen JH, Lai HY, et al. E-Cigarette Exposure Decreases Bone Marrow; 2020.

52.

Engel L, Beaton DE, Touma Z. Minimum clinically important difference - a review of outcome measure score interpretation. Rheum Dis Clin N Am. 2018;44(14):177–88. https://doi.org/10.1097/BRS.0000000000001990.CrossRef

Title: Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care
Authors: Sarah F. Christensen
Robyn M. Scherber
Gina L. Mazza
Amylou C. Dueck
Nana Brochmann
Christen L. Andersen
Hans C. Hasselbalch
Ruben A. Mesa
Holly L. Geyer
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Care
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08439-7

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Colorectal cancer survival among Ministry of National Guard-Health Affairs (MNG-HA) population 2009–2017: retrospective study

Cell-free DNA and circulating tumor cell kinetics in a pre-clinical head and neck Cancer model undergoing radiation therapy

Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China

Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells

NR1D1 suppressed the growth of ovarian cancer by abrogating the JAK/STAT3 signaling pathway